IFNa2b has been used to treat COVID 19 in China.² Subject to receiving marketing authorization, AP-003 could potentially be used to treat patients early after COVID 19 infection which may potentially prevent the progression to severe disease and need for hospitalization.³
- Through its wholly-owned
subsidiary, Altum Pharmaceuticals Inc.
- Dong et al, 2020; Lu, 2020; Shen & Yang, 2020; Zhou et al, 2020
- Altum Clin Protocol ALT 003 COV 01 2020 04 30
If successful in clinical trials, AP-003 may potentially be positioned as an initial treatment for COVID 19 and similar viruses.